The OncoAlert Newsletter
The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!
The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment…
An overview of ASCO’s policies and safeguards for relationships with companies, including frequently asked questions and editorials from ASCO’s senior staff.
Schoen’s handling of Nick McCloud raised eyebrows
At the free, LIVE class, you’ll get everything you need to make your decision & upgrade your job in 2025, regardless if you stay or…
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…
Immortal time may arise in survival analyses when individuals are assigned to treatment strategies based on post-eligibility information or selected based on post-assignment eligibility criteria.…
Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 500+ Peer Reviewed papers,…
Among patients with high-risk localized renal cell carcinoma, recurrence rates range from 40% to 50% after partial or radical nephrectomy, establishing a critical need for…
Genomics is an increasingly important part of biology research. However, educating undergraduates in genomics is not yet a standard part of life sciences curricula. We…
Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and…